Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 1
2021 2
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
van Veelen A, Veerman GDM, Verschueren MV, Gulikers JL, Steendam CMJ, Brouns AJWM, Dursun S, Paats MS, Tjan-Heijnen VCG, van der Leest C, Dingemans AC, Mathijssen RHJ, van de Garde EMW, Souverein P, Driessen JHM, Hendriks LEL, van Geel RMJM, Croes S. van Veelen A, et al. Int J Cancer. 2024 Jan 15;154(2):332-342. doi: 10.1002/ijc.34742. Epub 2023 Oct 15. Int J Cancer. 2024. PMID: 37840304
Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma.
Gulikers JL, van Veelen AJ, Sinkiewicz EMJ, de Beer YM, Slikkerveer M, Stolk LML, Tjan-Heijnen VCG, Hendriks LEL, Croes S, van Geel RMJM. Gulikers JL, et al. Among authors: van veelen aj. Biomed Chromatogr. 2023 Jun;37(6):e5628. doi: 10.1002/bmc.5628. Epub 2023 Apr 12. Biomed Chromatogr. 2023. PMID: 36941218
Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.
van Veelen A, Abtahi S, Souverein P, Driessen JHM, Klungel OH, Dingemans AC, van Geel R, de Vries F, Croes S. van Veelen A, et al. Cancer Epidemiol. 2022 Jun;78:102149. doi: 10.1016/j.canep.2022.102149. Epub 2022 Apr 13. Cancer Epidemiol. 2022. PMID: 35429893 Free article. Clinical Trial.
11 results